Published in Am J Trop Med Hyg on December 01, 2010
Malaria medicines: a glass half full? Nat Rev Drug Discov (2015) 2.53
The global pipeline of new medicines for the control and elimination of malaria. Malar J (2012) 1.57
Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. Expert Opin Drug Metab Toxicol (2011) 1.01
Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine. Int J Parasitol Drugs Drug Resist (2014) 0.89
Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients. PLoS One (2017) 0.81
Case Study of Small Molecules As Antimalarials: 2-Amino-1-phenylethanol (APE) Derivatives. ACS Med Chem Lett (2014) 0.79
Alternatives to currently used antimalarial drugs: in search of a magic bullet. Infect Dis Poverty (2016) 0.75
A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans. Malar J (2012) 0.75
Parasite physiology: No longer lost in translation. Nat Microbiol (2017) 0.75
Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet (1993) 5.99
Effectiveness of antimalarial drugs. N Engl J Med (2005) 4.83
Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ (2003) 2.87
Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci (1997) 2.23
Long-term malaria prophylaxis with weekly mefloquine. Lancet (1993) 2.09
Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis (2009) 1.75
The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review. Psychopharmacology (Berl) (1980) 1.67
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology (2003) 1.50
Adenosine-dopamine interactions in the brain. Neuroscience (1992) 1.39
Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet (2001) 1.38
Pharmacology of adenosine A2A receptors. Trends Pharmacol Sci (1996) 1.23
Mefloquine kinetics in cured and recrudescent patients with acute falciparum malaria and in healthy volunteers. Clin Pharmacol Ther (1990) 1.21
In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum. Br J Clin Pharmacol (1992) 1.19
Adenosine A2A receptors and Parkinson's disease. Handb Exp Pharmacol (2009) 1.18
Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. Bull World Health Organ (1990) 1.14
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl) (1999) 1.06
Plasmodium falciparum: role of absolute stereochemistry in the antimalarial activity of synthetic amino alcohol antimalarial agents. Exp Parasitol (1993) 1.01
Relative tolerability of Alzheimer's disease treatments. Psychiatry (Edgmont) (2008) 0.99
Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. J Pharm Sci (1994) 0.96
Tolerance of mefloquine by SwissAir trainee pilots. Am J Trop Med Hyg (1997) 0.92
Mefloquine for preventing malaria in non-immune adult travellers. Cochrane Database Syst Rev (2000) 0.90
Stereospecific inhibition of cholinesterases by mefloquine enantiomers. Chem Pharm Bull (Tokyo) (1987) 0.84
Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. Int J Clin Pharmacol Res (1995) 0.79
Adverse events associated with mefloquine. Study in returned travellers confirms authors' findings. BMJ (1996) 0.78
Understanding physical activity environmental correlates: increased specificity for ecological models. Exerc Sport Sci Rev (2005) 4.89
The International Prevalence Study on Physical Activity: results from 20 countries. Int J Behav Nutr Phys Act (2009) 3.99
Developing a framework for assessment of the environmental determinants of walking and cycling. Soc Sci Med (2003) 3.63
Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J Natl Cancer Inst (2012) 2.71
Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg (2007) 2.58
An applied ecological framework for evaluating infrastructure to promote walking and cycling: the iConnect study. Am J Public Health (2011) 2.19
Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol (2005) 1.82
Estimating the burden of disease attributable to physical inactivity in South Africa in 2000. S Afr Med J (2007) 1.69
Promotion of physical activity in the European region: content analysis of 27 national policy documents. J Phys Act Health (2009) 1.66
Effectiveness of a pragmatic education program designed to promote walking activity in individuals with impaired glucose tolerance: a randomized controlled trial. Diabetes Care (2009) 1.61
The influence of urban design on neighbourhood walking following residential relocation: longitudinal results from the RESIDE study. Soc Sci Med (2012) 1.59
The global pipeline of new medicines for the control and elimination of malaria. Malar J (2012) 1.57
Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J (2011) 1.56
Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One (2011) 1.54
Effect of questionnaire length, personalisation and reminder type on response rate to a complex postal survey: randomised controlled trial. BMC Med Res Methodol (2011) 1.50
An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One (2010) 1.48
A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS One (2011) 1.47
Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. Malar J (2011) 1.42
Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med (2012) 1.36
Can a single question provide an accurate measure of physical activity? Br J Sports Med (2012) 1.25
Understanding dog owners' increased levels of physical activity: results from RESIDE. Am J Public Health (2007) 1.20
Progress and pitfalls in the use of the International Physical Activity Questionnaire (IPAQ) for adult physical activity surveillance. J Phys Act Health (2009) 1.19
Challenges in antimalarial drug discovery. Future Med Chem (2011) 1.17
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Blood (2012) 1.16
First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol (2013) 1.15
Review of pyronaridine anti-malarial properties and product characteristics. Malar J (2012) 1.12
A simplified intravenous artesunate regimen for severe malaria. J Infect Dis (2011) 1.11
Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells. Toxicol Appl Pharmacol (2009) 1.09
Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malar J (2012) 1.08
Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res (2007) 1.05
Long-term sedentary work and the risk of subsite-specific colorectal cancer. Am J Epidemiol (2011) 1.02
Rationale, design and baseline data from the Pre-diabetes Risk Education and Physical Activity Recommendation and Encouragement (PREPARE) programme study: a randomized controlled trial. Patient Educ Couns (2008) 1.01
The association between neighborhood greenness and weight status: an observational study in Perth Western Australia. Environ Health (2013) 0.94
Specific modulation of astrocyte inflammation by inhibition of mixed lineage kinases with CEP-1347. J Immunol (2004) 0.94
Rapid changes in lifestyle make increased physical activity a priority for the Americas. Rev Panam Salud Publica (2003) 0.93
HIF prolyl hydroxylase inhibition increases cell viability and potentiates dopamine release in dopaminergic cells. J Neurochem (2010) 0.93
A new urban planning code's impact on walking: the residential environments project. Am J Public Health (2013) 0.92
Targeted expression of BCL-2 attenuates MPP+ but not 6-OHDA induced cell death in dopaminergic neurons. Neurobiol Dis (2003) 0.90
Chronic disease risk factors, healthy days and medical claims in South African employees presenting for health risk screening. BMC Public Health (2008) 0.90
Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg (2009) 0.90
Timing and intensity of recreational physical activity and the risk of subsite-specific colorectal cancer. Cancer Causes Control (2011) 0.89
Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle. BMC Clin Pharmacol (2007) 0.89
An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol (2011) 0.89
Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects. J Clin Pharmacol (2014) 0.88
Inflammation in Parkinson's disease: causative or epiphenomenal? Subcell Biochem (2007) 0.87
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol (2007) 0.87
The impact of the built environment on health across the life course: design of a cross-sectional data linkage study. BMJ Open (2013) 0.84
Malaria Prevalence among Young Infants in Different Transmission Settings, Africa. Emerg Infect Dis (2015) 0.84
Repositioning: the fast track to new anti-malarial medicines? Malar J (2014) 0.83
Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects. Br J Clin Pharmacol (2013) 0.83
Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects. Pharmacology (2012) 0.83
Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. Eur J Clin Pharmacol (2009) 0.82
A formative evaluation of a family-based walking intervention-Furness Families Walk4Life. BMC Public Health (2011) 0.82
In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium species. Antimicrob Agents Chemother (2011) 0.81
Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers. Am J Trop Med Hyg (2012) 0.81
Resistance training and the risk of colon and rectal cancers. Cancer Causes Control (2012) 0.81
Walking and inflammatory markers in individuals screened for type 2 diabetes. Prev Med (2008) 0.80
In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models. Drug Des Devel Ther (2013) 0.79
Public health recommendations for physical activity in the prevention of type 2 diabetes mellitus. Med Sport Sci (2014) 0.79
Tackling chronic disease through increased physical activity in the Arab World and the Middle East: challenge and opportunity. Br J Sports Med (2013) 0.79
Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers. Eur J Drug Metab Pharmacokinet (2014) 0.78
Global Advocacy for Physical Activity (GAPA): global leadership towards a raised profile. Glob Health Promot (2013) 0.77
People living in hilly residential areas in metropolitan Perth have less diabetes: spurious association or important environmental determinant? Int J Health Geogr (2013) 0.77
Effects of body size and gender on the population pharmacokinetics of artesunate and its active metabolite dihydroartemisinin in pediatric malaria patients. Antimicrob Agents Chemother (2013) 0.77
Defining physical inactivity. Lancet (2003) 0.75
Response. J Natl Cancer Inst (2013) 0.75
[Free radicals and ailing proteins--the culprits behind Parkinson disease?]. Lakartidningen (2003) 0.75
BMI-referenced cut-points for recommended daily pedometer-determined steps in Australian children and adolescents. Res Q Exerc Sport (2011) 0.75
Getting Scotland on the move? Reflections on a 5-year review of Scotland's national physical activity strategy. Br J Sports Med (2013) 0.75